Biogenerics: Opportunity v.s Threat

The generic companies are eyeing the potential of biogenerics, as the market for generic products is declining due to the rising costs and more competition. Biogenerics offer a tremendous scope for generic players to capture the unexplored lucarative market. It is estimated that by the end of 2010 nearly half of all new approved pharmaceuticals will be biopharmaceuticals and that $60-80 billion worth of biopharmaceuticals will be going off patent in the next few years. The manufacturing and processing of biogenerics is not an easy task and is a challenging field for generic manufacturer. Although Biognerics bill got positive opinion from European authorities, however, the same bill is under review in US market. Generic player, Dr. Reddy has also collaborated in the field of Biogenerics with various firms as reported earlier by IPPHARMADOC Here.
An article by Zelda Pickup and Andrew Whitworth CMS Cameron McKenna, published in pharmalicensing.com has highlighted the potential of biogenerics Here